Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

While Bryan was making his observations with the CD8–ζ chain chimera, a very talented group of postdoctoral fellows in my laboratory were on the hunt for a TCR-associated tyrosine kinase that ...

Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary resistance have ...

Let’s talk about insider trading. Not the illegal kind, but the perfectly normal – and fully legal – trading by top-level ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

本次ESMO大会进一步更新报道了中国桥接研究的数据。这项Ⅱ期研究招募了对伊马替尼治疗失败或不耐受的GIST成年患者，随机（1:1）接受瑞派替尼150 mg每日一次（QD）或舒尼替尼50 mg ...

历经多年不懈探索，奥希替尼在 EGFR 突变 NSCLC 治疗领域不断突破，至今已 8 次荣登 NEJM，成为其传奇历程的见证。与此同时，奥希替尼的应用范围不断扩大，从晚期扩展到早期，从后线治疗走向前线治疗，从单药治疗到联合治疗，其在国内已有 4 个适应症获批上市，是目前国内适应症范围最广*的 EGFR-TKI。而且，奥希替尼是目前唯一*的一线、二线及辅助治疗适应症均纳入医保的三代 ...

Nuvalent's promising lead candidates and strong investor interest has put the stock under the spotlight. Read more about the ...

Erlotinib is a quinazoline derivative that selectively and reversibly inhibits the tyrosine kinase activity of the EGFR. Here, we review the mechanism(s) of action of erlotinib, as well as the ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report).